Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Armonk, NY
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Armonk, NY
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Great Neck, NY
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Great Neck, NY
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Wilmington, NC
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dayton, OH
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Pottsville, PA
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Pottsville, PA
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Sayre, PA
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Sayre, PA
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Greenville, SC
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chattanooga, TN
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Memphis, TN
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dallas, TX
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Tyler, TX
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chesapeake, VA
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Norfolk, VA
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Spokane, WA
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated:  3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Appleton, WI
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients
Status: Enrolling
Updated: 3/12/2018
AOI Pharmaceuticals Investigative Site
mi
from
Appleton, WI
Click here to add this to my saved trials
Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery
Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients
Status: Enrolling
Updated:  3/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery
Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients
Status: Enrolling
Updated: 3/13/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
Status: Enrolling
Updated:  3/13/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy
Status: Enrolling
Updated: 3/13/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Joliet Oncology-Hematology Associates, Ltd.
mi
from
Joliet, IL
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Indiana University Health
mi
from
Goshen, IN
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Indiana University Health
mi
from
Goshen, IN
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Maryland Oncology Hematology, P.A.
mi
from
Rockville, MD
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Maryland Oncology Hematology, P.A.
mi
from
Rockville, MD
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Mount Sinai Beth Israel
mi
from
New York, NY
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Mount Sinai Beth Israel
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Medical University of South Carolina
mi
from
Charleston, SC
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Mary Crowley Cancer Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  3/15/2018
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 3/15/2018
Montefiore Einstein Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated:  3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Status: Enrolling
Updated: 3/20/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of California, San Diego
mi
from
San Diego, CA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of Pittsburgh Cancer Center
mi
from
Pittsburgh, PA
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of Pittsburgh Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
University of Vanderbilt
mi
from
Nashville, TN
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
University of Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated:  3/21/2018
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver
Status: Enrolling
Updated: 3/21/2018
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Fundacion Jimenez Diaz
mi
from
Madrid,
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Fundacion Jimenez Diaz
mi
from
Madrid,
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Montefiore Medical Center
mi
from
New York, NY
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Rhode Island Hospital
mi
from
Providence, RI
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Miriam Hospital
mi
from
Providence, RI
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
University of Southern CA
mi
from
Los Angeles, CA
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
University of Southern CA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Florida Hospital
mi
from
Florida City, FL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Florida Hospital
mi
from
Florida City, FL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Tampa General Hospital
mi
from
Tampa, FL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
University of Chicago
mi
from
Chicago, IL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Ochsner Clinic Foundation
mi
from
Jefferson, LA
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Ochsner Clinic Foundation
mi
from
Jefferson, LA
Click here to add this to my saved trials